Carlsen J E, Kardel T, Hilden T, Tangø M, Trap-Jensen J
Clin Physiol. 1981 Aug;1(4):375-84. doi: 10.1111/j.1475-097x.1981.tb00905.x.
The purpose of this study was to evaluate the immediate central and peripheral haemodynamic effects of a new vasodilating agent P 1134, in hypertensive man. After oral administration of 25 mg P 1134, the maximal haemodynamic changes were (mean +/- 1 SEM): mean blood pressure fell from 121.8 +/- 6.5 to 80.5 +/- 7.8 mmHg, heart rate increased 24.2 +/- 4.5 beats/min, cardiac output rose 2.9 +/- 0.3 1/min and forearm blood flow increased 1.0 +/- 0.1 ml/100 ml tissue/min. Stroke volume increased 17.0 +/- 2.1 ml and the inotropic state of the heart as judged from systolic time intervals increased. Total peripheral resistance and forearm vascular resistance were both reduced by approx. 50%. Linear correlations were found between the serum concentration of P 1134 and the change in mean blood pressure and total peripheral resistance. Changes in the other parameters mentioned above occurred progressively with changes in mean blood pressure and total peripheral resistance. It can be concluded that P 1134 is a very potent hypotensive agent with a haemodynamic profile identical to that seen with vasodilators with preferably act on precapillary resistance vessels. Potency and maximal efficacy exceeds that of hydralazine and seems like that of minoxidil. P 1134 is remarkably free from side-effects apart from causing water retention as all other vasodilators. It can be administered orally as well as intravenously. This makes P 1134 a very interesting compound in the treatment of moderate to severe hypertension, and further studies are well-founded.
本研究的目的是评估新型血管扩张剂P 1134对高血压患者即刻的中心和外周血流动力学效应。口服25 mg P 1134后,最大血流动力学变化为(均值±1标准误):平均血压从121.8±6.5 mmHg降至80.5±7.8 mmHg,心率增加24.2±4.5次/分钟,心输出量增加2.9±0.3升/分钟,前臂血流量增加1.0±0.1毫升/100毫升组织/分钟。每搏输出量增加17.0±2.1毫升,根据收缩期时间间期判断心脏的变力状态增强。总外周阻力和前臂血管阻力均降低约50%。发现P 1134的血清浓度与平均血压和总外周阻力的变化之间存在线性相关性。上述其他参数的变化随平均血压和总外周阻力的变化而逐渐发生。可以得出结论,P 1134是一种非常有效的降压药,其血流动力学特征与主要作用于毛细血管前阻力血管的血管扩张剂相同。其效力和最大疗效超过肼屈嗪,似乎与米诺地尔相当。除了像所有其他血管扩张剂一样引起水潴留外,P 1134几乎没有副作用。它既可以口服也可以静脉给药。这使得P 1134在治疗中度至重度高血压方面成为一种非常有吸引力的化合物,进一步的研究是有充分依据的。